NextCure, Inc.
NXTC
Rank in Stocks
#25044
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to... NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Share Price
$6.27
Last synced: 2026-11-09
Market Cap
$28.70M
Change (1 day)
17.64%
Change (1 year)
-26.41%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade NextCure, Inc. (NXTC)
Category
Healthcare
EPS for NextCure, Inc. (NXTC)
EPS as of June 2026 TTM: $-10.58
According to NextCure, Inc.'s latest financial reports, its current EPS (TTM) is $-10.58. At the end of 2025 the company had an EPS of $-19.65, an increase over its 2024 EPS of $-23.88.
EPS history for NextCure, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-10.58 | -46.16% |
| 2025 | $-19.65 | -17.71% |
| 2024 | $-23.88 | -11.68% |
| 2023 | $-27.04 | -16.35% |
| 2022 | $-32.32 | 7.20% |
| 2021 | $-30.15 | 89.00% |
| 2020 | $-15.95 | -38.15% |
| 2019 | $-25.79 | 114.15% |
| 2018 | $-12.04 | 47.39% |
| 2017 | $-8.17 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -248.02% |
US
|
|
| $-7.07 | -33.18% |
US
|
|
| $-5.29 | -50.00% |
AU
|
|
| $12.88 | -221.74% |
BE
|
|
| $21.56 | -303.78% |
NL
|
Questions about NextCure, Inc.'s earnings per share (EPS)
What is NextCure, Inc.'s earnings per share (EPS)?
NextCure, Inc.'s earnings per share (EPS) over the last twelve months is $-10.58, as of Jun 2026.
What was NextCure, Inc.'s earnings per share (EPS) in 2025?
In 2025, NextCure, Inc.'s earnings per share (EPS) was $-19.65, compared with $-23.88 in 2024.
How has NextCure, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, NextCure, Inc.'s earnings per share (EPS) was highest in 2020 ($-15.95) and lowest in 2022 ($-32.32).
How does NextCure, Inc.'s earnings per share (EPS) compare with similar companies?
NextCure, Inc.'s earnings per share (EPS) ($-10.58) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.